By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Chris Hoyt Knocking on the door of neuroscience drug approvals. SNAPSHOT KeifeRx has a full range of neuroscience (NS) drug candidates in development, spanning later-stage clinical assets to several novel, pre-IND technologies. Nilotinib (coded KFRX01) is close to entering a Phase 2b trial for treating early Alzheimer’s disease; and bosutinib (KFRX02) is ready to enter a Phase 2b trial in Lewy body dementia. Nilotinib is a reformulation of the existing drug branded as Tasigna, a tyrosine kinase inhibitor (TKI) indicated for chronic myeloid leukemia. Keife
Hence then, the article about companies to watch keiferx was published today ( ) and is available onTOP world News today ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Companies To Watch: KeifeRx )